Spinal Muscular Atrophy Foundation provides funding to support the discovery and advancement of novel products to treat SMA
New York, NY – March 03, 2005 – Researchers at Columbia University have received more than $3 million in funding from the Spinal Muscular Atrophy Foundation to conduct research on spinal muscular atrophy (SMA), a neuromuscular disease that is the leading genetic killer of infants and toddlers. The funding will enable the institution to significantly expand its already substantial SMA research.
With an estimated 55,000 people afflicted with the disease in the United States, Europe and Japan, spinal muscular atrophy, once among the least understood diseases in medicine, has recently emerged as one of the genetic conditions closest to a treatment. The National Institute of Neurological Disorders and Stroke (NINDS) has selected SMA to serve as the prototype for a translational research project that is expected to yield drug candidates for investigational new drug application filings by 2007. The SMA Foundation has been instrumental in raising awareness and supporting ground breaking SMA projects in biotechnology, government and academia which will advance translational research overall, including the efforts underway at NIH.
The SMA Foundation's donation to Columbia University research is part of a broader strategy to integrate basic, translational and clinical research efforts at leading institutions into coordinated efforts aimed at facilitating drug discovery.
Loren Eng, Co-Founder and President of the SMA Foundation, said, "Columbia University was an obvious place to launch this effort given the institution's leadership position in neuroscience and neurology. In the past four years Columbia neuroscientists have won two Nobel prizes. There is also a strong commitment to neuroscience from Columbia's administration and research community. One third of all Columbia researchers study the brain and nervous system and they generate more research funding than any other group of neuroscientists in the country. Given the strengths of the institution and its people, it was evident that Columbia was the place for us to develop an SMA research nucleus."
Most recently, Columbia University president Lee Bollinger and Columbia University Medical Center (CUMC) executive vice president and dean Gerald Fischbach, M.D. announced the creation of a Neuroscience Institute which will bring together researchers and clinicians to expedite discoveries from the laboratory to the bedside.
"This a remarkable time in the field of neuroscience and SMA research," said Dr. Fischbach. "Given all that is already known about SMA scientifically, the expanded research that this funding supports will greatly advance the probability of a treatment in the near term. The funding provided by the Foundation will enable us to provide critical support to rapidly advance our research and clinical care to patients with SMA. "
Key Columbia faculty members who have been funded by the SMA Foundation or are involved in SMA research include:
Umrao Monani, Ph.D., Assistant Professor of Neurology in the Center of Neurobiology and Behavior at CUMC is responsible for identifying drug targets. He was instrumental in the development of a key mouse model of SMA, which is essential to genetic studies of the disease. His research addresses the question of why a decreased amount of Survival Motor Neuron (SMN) protein leads to SMA and provides an opportunity to test the drugs that Dr. Stockwell identifies.
Brent Stockwell, Ph.D., Assistant Professor in the Department of Biological Sciences and the Department of Chemistry at Columbia University leads drug discovery efforts. He focuses on chemical genetics, drug discovery and is screening tens of thousands of existing compounds to identify drugs that will stimulate the creation of SMN protein, which is deficient in SMA patients.
Christopher E. Henderson, Ph.D., a neurobiologist specializing in central nervous system development and neuronal degeneration will be joining the institution. Dr. Henderson will establish a Center for Motor Neuron Biology and Disease at CUMC focused on high-level translational motor neuron research. Working collaboratively with each laboratory and contributing to the translational research process, the new center will facilitate transfer of screening techniques, active chemical molecules and knowledge of disease causing pathways.
Darryl De Vivo, M.D., the Sidney Carter Professor of Neurology at CUMC and the director of the SMA Clinic, will direct the next step toward bringing new therapies to SMA patients through clinical trials. Dr. De Vivo is leading a multi-center network of investigators – the Pediatric Neuromuscular Clinical Research Network – that includes CUMC, Harvard University and the University of Pennsylvania researchers, as well as data management from the University of Rochester. Beginning in 2005, Dr. De Vivo and the network will conduct clinical trials in SMA patients with drugs that are currently under study as well as any compounds newly discovered by Dr. Stockwell, Dr. Monani and others. It is hoped that one more of these drugs candidates will significantly reduce the devastating effects of SMA in patients.
James L. Manley, Ph.D., a molecular biologist and Julian Clarence Levi Professor of Life Sciences in the Department of Biological Sciences at Columbia University is studying, together with his colleague Tsuyoshi Kashima, M.D., the basic biology of the SMN gene to find ways in which to recover its activity in patients. He is interested in how information in the chromosome is converted into messenger RNA to produce the SMN protein and is trying to understand the defect in that process that results in SMA disease.
Thomas Jessell, Ph.D., Investigator at the Howard Hughes Medical Institute and Director of the Neuroscience Institute at Columbia University, is focused on defining the molecular mechanisms that control motor neuron differentiation and the formation of sensory-motor circuitry in the developing spinal cord. Recent studies together with Hynek Wichterle, Ph.D., now in the Department of Pathology at Columbia University Medical Center, have been able to convert embryonic stem cells into functional motor neurons, opening up new strategies for cell based chemical screens for drugs that can prevent the degeneration of motor neurons associated with SMA.
Committed to supporting research with the highest probability of advancing potential drug candidates, the SMA Foundation has forged collaborations with leading medical institutions and industry in the United States and internationally. Since its inception, the Foundation has funded more than $15 million in research initiatives, formed a number of partnerships with biotechnology companies, reduced barriers in the drug development process by providing open access to mouse models of SMA and has been instrumental in working with both Congress and the National Institutes of Health in creating awareness and increasing federal funding for the disease.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
Happiness is having a large, loving, caring, close-knit family -- in another city.
-- George Burns